SILO Fundamental Analysis - SILO PHARMA INC

Name: SILO PHARMA INC (SILO) Stock
Brand: SILO PHARMA INC
Rating: 4 (3 reviews)

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to SILO. SILO was compared to 531 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for SILO as it has an excellent financial health rating, but there are worries on the profitability. SILO has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year SILO has reported negative net income.

In the past year SILO has reported a negative cash flow from operations.

SILO had negative earnings in 4 of the past 5 years.

SILO had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

With a Return On Assets value of -73.58%, SILO is not doing good in the industry: 63.62% of the companies in the same industry are doing better.

With a Return On Equity value of -99.55%, SILO perfoms like the industry average, outperforming 45.52% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-73.58%
ROE	-99.55%
ROIC	N/A

ROA(3y)-46.88%

ROA(5y)-66.86%

ROE(3y)-61.66%

ROE(5y)-80.07%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

SILO has a better Gross Margin (92.22%) than 92.72% of its industry peers.

In the last couple of years the Gross Margin of SILO has grown nicely.

The Profit Margin and Operating Margin are not available for SILO so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	92.22%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-2.76%

GM growth 5Y29.76%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

SILO does not have a ROIC to compare to the WACC, probably because it is not profitable.

SILO has more shares outstanding than it did 1 year ago.

SILO has more shares outstanding than it did 5 years ago.

There is no outstanding debt for SILO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -3.14, we must say that SILO is in the distress zone and has some risk of bankruptcy.

SILO has a Altman-Z score (-3.14) which is comparable to the rest of the industry.

There is no outstanding debt for SILO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-3.14

ROIC/WACCN/A

WACC8.75%

2.3 Liquidity

SILO has a Current Ratio of 6.07. This indicates that SILO is financially healthy and has no problem in meeting its short term obligations.

SILO has a Current ratio of 6.07. This is in the better half of the industry: SILO outperforms 63.81% of its industry peers.

A Quick Ratio of 6.07 indicates that SILO has no problem at all paying its short term obligations.

Looking at the Quick ratio, with a value of 6.07, SILO is in the better half of the industry, outperforming 64.37% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	6.07
Quick Ratio	6.07

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 12.91% over the past year.

Looking at the last year, SILO shows a decrease in Revenue. The Revenue has decreased by -2.70% in the last year.

Measured over the past years, SILO shows a quite strong growth in Revenue. The Revenue has been growing by 12.51% on average per year.

EPS 1Y (TTM)12.91%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%37.16%

Revenue 1Y (TTM)-2.7%

Revenue growth 3Y0.99%

Revenue growth 5Y12.51%

Sales Q2Q%0%

3.2 Future

The Earnings Per Share is expected to decrease by -21.62% on average over the next years. This is quite bad

SILO is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by 0.00% yearly.

EPS Next Y-25%

EPS Next 2Y-13.39%

EPS Next 3Y-25.99%

EPS Next 5Y-21.62%

Revenue Next Year0%

Revenue Next 2Y0%

Revenue Next 3Y0%

Revenue Next 5Y0%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

SILO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year SILO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A cheap valuation may be justified as SILO's earnings are expected to decrease with -25.99% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-13.39%

EPS Next 3Y-25.99%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for SILO!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

SILO PHARMA INC

NASDAQ:SILO (11/7/2025, 8:17:43 PM)

After market: 0.4552 -0.01 (-1.58%)

0.4625

-0.03 (-6.22%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)08-13 2025-08-13

Earnings (Next)11-10 2025-11-10

Inst Owners4.3%

Inst Owner Change44.4%

Ins Owners2.18%

Ins Owner Change4.93%

Market Cap6.16M

Revenue(TTM)72.00K

Net Income(TTM)-4.90M

Analysts82.86

Price TargetN/A

Short Float %8.49%

Short Ratio0.66

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	85.56
P/FCF	N/A
P/OCF	N/A
P/B	1.25
P/tB	1.31
EV/EBITDA	N/A

EPS(TTM)-1.02

EYN/A

EPS(NY)-0.73

Fwd EYN/A

FCF(TTM)-0.39

FCFYN/A

OCF(TTM)-0.39

OCFYN/A

SpS0.01

BVpS0.37

TBVpS0.35

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-73.58%
ROE	-99.55%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	92.22%
FCFM	N/A

ROA(3y)-46.88%

ROA(5y)-66.86%

ROE(3y)-61.66%

ROE(5y)-80.07%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-2.76%

GM growth 5Y29.76%

F-Score3

Asset Turnover0.01

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	6.07
Quick Ratio	6.07
Altman-Z	-3.14

F-Score3

WACC8.75%

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)12.91%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%37.16%

EPS Next Y-25%

EPS Next 2Y-13.39%

EPS Next 3Y-25.99%

EPS Next 5Y-21.62%

Revenue 1Y (TTM)-2.7%

Revenue growth 3Y0.99%

Revenue growth 5Y12.51%

Sales Q2Q%0%

Revenue Next Year0%

Revenue Next 2Y0%

Revenue Next 3Y0%

Revenue Next 5Y0%

EBIT growth 1Y-35.38%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-46.18%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-46.18%

OCF growth 3YN/A

OCF growth 5YN/A

SILO PHARMA INC / SILO FAQ

What is the fundamental rating for SILO stock?

ChartMill assigns a fundamental rating of 3 / 10 to SILO.

Can you provide the valuation status for SILO PHARMA INC?

ChartMill assigns a valuation rating of 0 / 10 to SILO PHARMA INC (SILO). This can be considered as Overvalued.

Can you provide the profitability details for SILO PHARMA INC?

SILO PHARMA INC (SILO) has a profitability rating of 2 / 10.

Can you provide the expected EPS growth for SILO stock?

The Earnings per Share (EPS) of SILO PHARMA INC (SILO) is expected to decline by -25% in the next year.

SILO PHARMA INC (SILO) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

SILO PHARMA INC / SILO FAQ

What is the fundamental rating for SILO stock?

Can you provide the valuation status for SILO PHARMA INC?

Can you provide the profitability details for SILO PHARMA INC?

Can you provide the expected EPS growth for SILO stock?